Abstract
Despite the availability of 15 approved drugs for the treatment of HIV infection, issues of convenience, tolerability, and antiretroviral activity make the continued development of newer drugs important. New drugs in clinical development represent both existing classes of antiretroviral agents--reverse transcriptase inhibitors (eg, diaminopurine dioxolane), nonnucleoside reverse transcriptase inhibitors (eg, capravirine), and protease inhibitors (eg, tipranavir and BMS-232632)--and newer classes of antiretroviral agents, such as nucleotide analogue reverse transcriptase inhibitors (eg, tenofovir) and fusion inhibitors (eg, pentafuside). Newer drugs may offer improvements over existing agents by having simpler dosing schedules (once or twice daily), better tolerability, or improved virologic activity against wild-type or resistant virus. Continued advancements in HIV treatment will stem from ongoing development of antiretroviral drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
